On April 15, 2022, Broadwood Capital, Inc. announced that it has been, and might continue to be, in contact with members of OncoCyte Corporation's management, the board of directors of the Company, other significant shareholders and others regarding alternatives that the Company could employ to maximize the creation of shareholder value over time.